[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Pravat Mandal\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":106},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,52,79],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100596799","phase-1-monitoring-patients-with-repetitive-head-impact-with-gamma-glutamylcysteine-supplementation-100596799",false,"NCT07050173","Monitoring Patients With Repetitive Head Impact With Gamma-glutamylcysteine Supplementation","Patients With Repetitive Head Impact Orally Supplemented With Gamma-glutamylcysteine: An Open Label Trial With MR Spectroscopy and Neuropsychological Testing","RHIGSH","Inclusion Criteria:\n\n* Retired NFL player, retired Navy SEAL\u002Farmy personnel with combat experience exposed to repetitive head impact;\n* Memory and behavioral complaint per self- or informant-report;\n* Age (30 to 70 years of age) years;\n* Able to read and write in English and to give consent to participate in the study.\n\nExclusion Criteria:\n\n* Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments in the eyes, skin, or body.\n* Subjects with claustrophobia.\n* Subject with mild cognitive impairment \\[TICS score of 29 or lower OR \\>=1.0 standard deviations below age-expectation on at least two cognitive members within the same cognitive domain (e.g. memory, attention, etc.) on the baseline neuropsychological testing;\n* Subjects with a history of cancer;\n* Subjects with active psychosis or delirium;\n* Subjects with chronic kidney (creatinine \\> 1.5mg\u002FdL) or liver disease (AST ≥ 1.5 ULN; ALT ≥1.5 ULN) within 30 days prior to enrollment;\n* Subjects on antioxidant therapy (gingko biloba or N-acetylcysteine) or illicit drug abuse\u002Fdependence (cocaine, heroin, marijuana, or fentanyl;\n* Repeated head injury patients with neurosurgical intervention and;\n* Subjects with repeated head injury within the last 90 days.","ALL","30 Years","70 Years",{"count":21,"type":22},30,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","The goal of this clinical trial is to test whether the gamma - glutamylcystiene (GGC) oral supplement can reach the brain and subsequently increase antioxidant glutathione (GSH) level in people with repetitive head impact (RHI). This will reduce the oxidative stress related injury in people with RHI.This unique study's main objective is to test the:\n\n1. Change in GSH in brain and blood levels through GGC supplementation.\n2. Change in the cognitive function in RHI patients due to GGC supplementation.",[28],"Repetitive Head Impacts",[30,31,32,33,34,35,36,37,38],"Brain injury","Glutathione","MR spectroscopy","Non- invasive","GGC","RHI","TES","Brain","Blood","RECRUITING","2026-06-01",{"date":42,"type":43},"2026-06-03","ACTUAL",{"date":45,"type":43},"2026-05-01",{"date":47,"type":22},"2027-12-27",{"name":49,"class":50},"Pravat Mandal","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":17,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":4,"studyType":23,"phases":64,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":51},"100639116","phase-1-safety-and-tolerability-of-gamma-glutamylcysteine-ggc-oral-supplementation-in-mci-patients-100639116","NCT07583251","Safety And Tolerability Of Gamma Glutamylcysteine (GGC) Oral Supplementation In MCI Patients","Study For Safety And Tolerability Of Gamma Glutamylcysteine (GGC) Oral Supplementation In MCI Patients","MCI-GSH","Inclusion Criteria:\n\n1. Memory complaints;\n2. MCI diagnosis\n3. MoCA score between 18-25\n4. Age 55 - 80 years old.\n5. Ability to read and write in English\n\nExclusion Criteria:\n\n1. Subjects with acute head trauma or head injury involving loss of consciousness;\n2. Subjects with a history of cancer;\n3. Subjects with a history of schizophrenia, manic-depressive disorder\n4. Subjects on antioxidant therapy (ashwagandha, gingko biloba, N-acetylcysteine or glutathione)\n5. Subjects on illicit drug (cocaine, heroin, marijuana, or fentanyl) abuse\u002Fdependence;","55 Years","80 Years",{"count":63,"type":22},9,[25],"The goal of this study is to evaluate the safety and tolerability of Gamma Glutamylcysteine (GGC) supplement at different doses (400mg\u002Fday or 800mg\u002Fday or 1200mg\u002Fday) when administered orally to patients with MCI over 3 months. This study is designed to generate preliminary clinical safety data to inform the feasibility and design of larger controlled trials.",[67],"Mild Cognitive Impairment (MCI)",[69,34,70,71],"GSH","MCI","cognitive","2026-05-29",{"date":42,"type":43},{"date":75,"type":22},"2026-06",{"date":77,"type":22},"2027-02",{"name":49,"class":50},{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":17,"minAge":87,"maxAge":61,"enrollmentInfo":88,"targetDuration":4,"studyType":23,"phases":90,"briefSummary":91,"conditions":92,"keywords":94,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":51},"100597862","phase-1-enrichment-of-glutathione-using-gamma-glutamylcysteine-supplementation-in-parkinsons-disease-patients-100597862","NCT07064005","Enrichment of Glutathione Using Gamma-glutamylcysteine Supplementation in Parkinson's Disease Patients.","Brain Glutathione (GSH) Enrichment Through Gamma-glutamylcysteine (GGC) Supplementation in Early Parkinson's Disease Patients for Reduction of Extrapyramidal Motor Disturbances and Halting Cognition Decline: A Pilot Trial","PDGSH","Inclusion Criteria:\n\n* Confirmed Parkinson's Disease diagnosis.\n* Montreal Cognitive Assessment (MoCA) greater than or equal to 26.\n* Age (50 to 80 years of age).\n* Ability to read and write in English.\n\nExclusion Criteria:\n\n* Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments in the eyes, skin, or body.\n* Subjects with claustrophobia.\n* Patients with a clinical diagnosis of Parkinson's disease dementia or dementia with Lewy bodies.\n* Subjects with a history of cancer.\n* Subjects with active psychosis or delirium.\n* Subjects with chronic kidney (creatinine \\> 1.5mg\u002FdL) or liver disease (AST ≥ 1.5 ULN; ALT ≥ 1.5 ULN) within 30 days prior to enrolment.\n* Subjects on antioxidant therapy (ashwagandha, gingko biloba or N-acetylcysteine) or illicit drug abuse\u002Fdependence (cocaine, heroin, marijuana, or fentanyl).\n* Subjects with previous traumatic head injury.","50 Years",{"count":89,"type":22},12,[25],"This study is designed l to evaluate the effects of GGC oral supplementation in early Parkinson's disease (PD) patients. The main objectives of the study are to evaluate:\n\n1. To study the enrichment of master antioxidant, glutathione (GSH) levels in brain and blood of these PD patients compared to baseline due to GGC supplementation.\n2. To study the changes in motor function, cognitive skills in PD patients due to GGC oral supplementation\n3. To study impact of GGC on gut health on the PD patients.",[93],"Parkinsons Disease (PD)",[38,37,95,34,31,96,97,98],"MR Spectroscopy","Parkinsons disease","Oxidative stress","Brain Iron",{"date":100,"type":43},"2026-05-04",{"date":102,"type":43},"2026-03-23",{"date":104,"type":22},"2027-11-27",{"name":49,"class":50},""]